Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1524 entries
Sorted by: Best Match Show Resources per page
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.

Breast cancer (Dove Medical Press)

Jerusalem G, Rorive A, Collignon J.
PMID: 24833916
Breast Cancer (Dove Med Press). 2014 Apr 17;6:43-57. doi: 10.2147/BCTT.S38679. eCollection 2014.

Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents. Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemestane, an...

Cite
Jerusalem G, Rorive A, Collignon J. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer (Dove Med Press). 2014;6:43-57doi: 10.2147/BCTT.S38679.
Jerusalem, G., Rorive, A., & Collignon, J. (2014). Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast cancer (Dove Medical Press), 643-57. https://doi.org/10.2147/BCTT.S38679
Jerusalem, Guy, et al. "Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes." Breast cancer (Dove Medical Press) vol. 6 (2014): 43-57. doi: https://doi.org/10.2147/BCTT.S38679
Jerusalem G, Rorive A, Collignon J. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer (Dove Med Press). 2014 Apr 17;6:43-57. doi: 10.2147/BCTT.S38679. eCollection 2014. PMID: 24833916; PMCID: PMC4000187.
Copy Download .nbib Format: NLM
Past, present, and future of hormonal therapy in recurrent endometrial cancer.

International journal of women's health

Carlson MJ, Thiel KW, Leslie KK.
PMID: 24833920
Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014.

Endometrial cancer is a heterogeneous disease. Type I cancers are hormonally driven, typically present with a low grade at an early stage, and are of endometrioid histology. These cancers are often cured by surgery, and the rate of recurrence...

Cite
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014;6:429-35doi: 10.2147/IJWH.S40942.
Carlson, M. J., Thiel, K. W., & Leslie, K. K. (2014). Past, present, and future of hormonal therapy in recurrent endometrial cancer. International journal of women's health, 6429-35. https://doi.org/10.2147/IJWH.S40942
Carlson, Matthew J, et al. "Past, present, and future of hormonal therapy in recurrent endometrial cancer." International journal of women's health vol. 6 (2014): 429-35. doi: https://doi.org/10.2147/IJWH.S40942
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014. PMID: 24833920; PMCID: PMC4014387.
Copy Download .nbib Format: NLM
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib.

Clinical and translational medicine

Shivapurkar N, Vietsch EE, Carney E, Isaacs C, Wellstein A.
PMID: 28980224
Clin Transl Med. 2017 Oct 04;6(1):37. doi: 10.1186/s40169-017-0169-y.

BACKGROUND: Serial analysis of biomarkers in the circulation of patients undergoing treatment ("liquid biopsies") can provide new insights into drug effects. In particular the analysis of cell-free, circulating nucleic acids such as microRNAs (miRs) can reveal altered expression patterns...

Cite
Shivapurkar N, Vietsch EE, Carney E, et al. Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. Clin Transl Med. 2017;6(1):37doi: 10.1186/s40169-017-0169-y.
Shivapurkar, N., Vietsch, E. E., Carney, E., Isaacs, C., & Wellstein, A. (2017). Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. Clinical and translational medicine, 6(1), 37. https://doi.org/10.1186/s40169-017-0169-y
Shivapurkar, Narayan, et al. "Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib." Clinical and translational medicine vol. 6,1 (2017): 37. doi: https://doi.org/10.1186/s40169-017-0169-y
Shivapurkar N, Vietsch EE, Carney E, Isaacs C, Wellstein A. Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. Clin Transl Med. 2017 Oct 04;6(1):37. doi: 10.1186/s40169-017-0169-y. PMID: 28980224; PMCID: PMC5628092.
Copy Download .nbib Format: NLM
Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence.

Surgical case reports

Adachi Y, Kikumori T, Miyajima N, Inaishi T, Onishi E, Shibata M, Nakanishi K, Takeuchi D, Hayashi H, Kodera Y.
PMID: 26943450
Surg Case Rep. 2015 Dec;1(1):126. doi: 10.1186/s40792-015-0128-z. Epub 2015 Dec 30.

Cancer antigen 15-3 (CA15-3) is considered as a marker for breast cancer recurrence. However, we encountered a case where the patient showed postoperative elevation of the CA15-3 level due to pernicious anemia without evidence of breast cancer recurrence. The...

Cite
Adachi Y, Kikumori T, Miyajima N, et al. Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence. Surg Case Rep. 2015;1(1):126doi: 10.1186/s40792-015-0128-z.
Adachi, Y., Kikumori, T., Miyajima, N., Inaishi, T., Onishi, E., Shibata, M., Nakanishi, K., Takeuchi, D., Hayashi, H., & Kodera, Y. (2015). Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence. Surgical case reports, 1(1), 126. https://doi.org/10.1186/s40792-015-0128-z
Adachi, Yayoi, et al. "Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence." Surgical case reports vol. 1,1 (2015): 126. doi: https://doi.org/10.1186/s40792-015-0128-z
Adachi Y, Kikumori T, Miyajima N, Inaishi T, Onishi E, Shibata M, Nakanishi K, Takeuchi D, Hayashi H, Kodera Y. Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence. Surg Case Rep. 2015 Dec;1(1):126. doi: 10.1186/s40792-015-0128-z. Epub 2015 Dec 30. PMID: 26943450; PMCID: PMC4696936.
Copy Download .nbib Format: NLM
Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole.

Gynecologic oncology reports

Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA.
PMID: 28393092
Gynecol Oncol Rep. 2017 Mar 14;20:93-96. doi: 10.1016/j.gore.2017.03.005. eCollection 2017 May.

OBJECTIVE: Ovarian anaplastic ependymoma is a rare gynecologic malignancy that poses diagnostic and treatment challenges. Treatment of sub-optimally debulked disease usually portends poor prognosis. Molecular testing of tumor specimen can identify more specific targets for additional therapy such as...

Cite
Gorski JW, Taylor JS, Zhang J, et al. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017;20:93-96doi: 10.1016/j.gore.2017.03.005.
Gorski, J. W., Taylor, J. S., Zhang, J., Liu, J., & Jazaeri, A. A. (2017). Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecologic oncology reports, 2093-96. https://doi.org/10.1016/j.gore.2017.03.005
Gorski, Justin Wayne, et al. "Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole." Gynecologic oncology reports vol. 20 (2017): 93-96. doi: https://doi.org/10.1016/j.gore.2017.03.005
Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017 Mar 14;20:93-96. doi: 10.1016/j.gore.2017.03.005. eCollection 2017 May. PMID: 28393092; PMCID: PMC5376265.
Copy Download .nbib Format: NLM
Immunolocalisation of aromatase regulators liver kinase B1, phosphorylated AMP-activated protein kinase and cAMP response element-binding protein-regulated transcription co-activators in the human testis.

Reproduction, fertility, and development

Ham S, Brown KA, Simpson ER, Meachem SJ.
PMID: 26946412
Reprod Fertil Dev. 2016 Mar 07; doi: 10.1071/RD15390. Epub 2016 Mar 07.

Although oestrogens are essential for spermatogenesis and their biosynthesis is dependent on aromatase expression, the molecular mechanism of aromatase regulation is poorly understood. Our laboratory has demonstrated that liver kinase B1 (LKB1) is a negative regulator of aromatase in...

Cite
Ham S, Brown KA, Simpson ER, et al. Immunolocalisation of aromatase regulators liver kinase B1, phosphorylated AMP-activated protein kinase and cAMP response element-binding protein-regulated transcription co-activators in the human testis. Reprod Fertil Dev. 2016;doi: 10.1071/RD15390.
Ham, S., Brown, K. A., Simpson, E. R., & Meachem, S. J. (2016). Immunolocalisation of aromatase regulators liver kinase B1, phosphorylated AMP-activated protein kinase and cAMP response element-binding protein-regulated transcription co-activators in the human testis. Reproduction, fertility, and development, . https://doi.org/10.1071/RD15390
Ham, Seungmin, et al. "Immunolocalisation of aromatase regulators liver kinase B1, phosphorylated AMP-activated protein kinase and cAMP response element-binding protein-regulated transcription co-activators in the human testis." Reproduction, fertility, and development vol. (2016). doi: https://doi.org/10.1071/RD15390
Ham S, Brown KA, Simpson ER, Meachem SJ. Immunolocalisation of aromatase regulators liver kinase B1, phosphorylated AMP-activated protein kinase and cAMP response element-binding protein-regulated transcription co-activators in the human testis. Reprod Fertil Dev. 2016 Mar 07; doi: 10.1071/RD15390. Epub 2016 Mar 07. PMID: 26946412.
Copy Download .nbib Format: NLM
Effects of chronic heat stress on granulosa cell apoptosis and follicular atresia in mouse ovary.

Journal of animal science and biotechnology

Li J, Gao H, Tian Z, Wu Y, Wang Y, Fang Y, Lin L, Han Y, Wu S, Haq I, Zeng S.
PMID: 27708774
J Anim Sci Biotechnol. 2016 Sep 29;7:57. doi: 10.1186/s40104-016-0116-6. eCollection 2016.

BACKGROUND: Heat stress is known to alter follicular dynamics and granulosa cell function and may contribute to the diminished reproductive efficiency commonly observed in mammals during the summer. Although several investigators have studied heat-induced ovarian injury, few reports have...

Cite
Li J, Gao H, Tian Z, et al. Effects of chronic heat stress on granulosa cell apoptosis and follicular atresia in mouse ovary. J Anim Sci Biotechnol. 2016;7:57doi: 10.1186/s40104-016-0116-6.
Li, J., Gao, H., Tian, Z., Wu, Y., Wang, Y., Fang, Y., Lin, L., Han, Y., Wu, S., Haq, I., & Zeng, S. (2016). Effects of chronic heat stress on granulosa cell apoptosis and follicular atresia in mouse ovary. Journal of animal science and biotechnology, 757. https://doi.org/10.1186/s40104-016-0116-6
Li, Jieyun, et al. "Effects of chronic heat stress on granulosa cell apoptosis and follicular atresia in mouse ovary." Journal of animal science and biotechnology vol. 7 (2016): 57. doi: https://doi.org/10.1186/s40104-016-0116-6
Li J, Gao H, Tian Z, Wu Y, Wang Y, Fang Y, Lin L, Han Y, Wu S, Haq I, Zeng S. Effects of chronic heat stress on granulosa cell apoptosis and follicular atresia in mouse ovary. J Anim Sci Biotechnol. 2016 Sep 29;7:57. doi: 10.1186/s40104-016-0116-6. eCollection 2016. PMID: 27708774; PMCID: PMC5043540.
Copy Download .nbib Format: NLM
Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism.

Journal of applied physiology (Bethesda, Md. : 1985)

Holland AM, Roberts MD, Mumford PW, Mobley CB, Kephart WC, Conover CF, Beggs LA, Balaez A, Otzel DM, Yarrow JF, Borst SE, Beck DT.
PMID: 27539493
J Appl Physiol (1985). 2016 Sep 01;121(3):792-805. doi: 10.1152/japplphysiol.00238.2016. Epub 2016 Aug 18.

The influence of the aromatase enzyme on the chronic fat-sparing effects of testosterone requires further elucidation. Our purpose was to determine whether chronic anastrozole (AN, an aromatase inhibitor) treatment alters testosterone-mediated lipolytic/lipogenic gene expression in visceral fat. Ten-month-old Fischer...

Cite
Holland AM, Roberts MD, Mumford PW, et al. Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism. J Appl Physiol (1985). 2016;121(3):792-805doi: 10.1152/japplphysiol.00238.2016.
Holland, A. M., Roberts, M. D., Mumford, P. W., Mobley, C. B., Kephart, W. C., Conover, C. F., Beggs, L. A., Balaez, A., Otzel, D. M., Yarrow, J. F., Borst, S. E., & Beck, D. T. (2016). Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism. Journal of applied physiology (Bethesda, Md. : 1985), 121(3), 792-805. https://doi.org/10.1152/japplphysiol.00238.2016
Holland, A Maleah, et al. "Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism." Journal of applied physiology (Bethesda, Md. : 1985) vol. 121,3 (2016): 792-805. doi: https://doi.org/10.1152/japplphysiol.00238.2016
Holland AM, Roberts MD, Mumford PW, Mobley CB, Kephart WC, Conover CF, Beggs LA, Balaez A, Otzel DM, Yarrow JF, Borst SE, Beck DT. Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism. J Appl Physiol (1985). 2016 Sep 01;121(3):792-805. doi: 10.1152/japplphysiol.00238.2016. Epub 2016 Aug 18. PMID: 27539493.
Copy Download .nbib Format: NLM
Endometriosis: alternative methods of medical treatment.

International journal of women's health

Muñoz-Hernando L, Muñoz-Gonzalez JL, Marqueta-Marques L, Alvarez-Conejo C, Tejerizo-García Á, Lopez-Gonzalez G, Villegas-Muñoz E, Martin-Jimenez A, Jiménez-López JS.
PMID: 26089705
Int J Womens Health. 2015 Jun 11;7:595-603. doi: 10.2147/IJWH.S78829. eCollection 2015.

Endometriosis is an inflammatory estrogen-dependent disease defined by the presence of endometrial glands and stroma at extrauterine sites. The main purpose of endometriosis management is alleviating pain associated to the disease. This can be achieved surgically or medically, although...

Cite
Muñoz-Hernando L, Muñoz-Gonzalez JL, Marqueta-Marques L, et al. Endometriosis: alternative methods of medical treatment. Int J Womens Health. 2015;7:595-603doi: 10.2147/IJWH.S78829.
Muñoz-Hernando, L., Muñoz-Gonzalez, J. L., Marqueta-Marques, L., Alvarez-Conejo, C., Tejerizo-García, �. �., Lopez-Gonzalez, G., Villegas-Muñoz, E., Martin-Jimenez, A., & Jiménez-López, J. S. (2015). Endometriosis: alternative methods of medical treatment. International journal of women's health, 7595-603. https://doi.org/10.2147/IJWH.S78829
Muñoz-Hernando, Leticia, et al. "Endometriosis: alternative methods of medical treatment." International journal of women's health vol. 7 (2015): 595-603. doi: https://doi.org/10.2147/IJWH.S78829
Muñoz-Hernando L, Muñoz-Gonzalez JL, Marqueta-Marques L, Alvarez-Conejo C, Tejerizo-García Á, Lopez-Gonzalez G, Villegas-Muñoz E, Martin-Jimenez A, Jiménez-López JS. Endometriosis: alternative methods of medical treatment. Int J Womens Health. 2015 Jun 11;7:595-603. doi: 10.2147/IJWH.S78829. eCollection 2015. PMID: 26089705; PMCID: PMC4468987.
Copy Download .nbib Format: NLM
Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.

OncoTargets and therapy

Jia XQ, Hong Q, Cheng JY, Li JW, Wang YJ, Mo M, Shao ZM, Shen ZZ, Liu GY.
PMID: 25767399
Onco Targets Ther. 2015 Mar 03;8:549-55. doi: 10.2147/OTT.S76879. eCollection 2015.

OBJECTIVE: Studies have indicated that p53 protein accumulation exerts an adverse effect on the survival of breast cancer patients; however, the prognostic value of p53 protein accumulation for aromatase inhibitor (AI) resistance in ER-positive breast cancer is uncertain.METHODS: The...

Cite
Jia XQ, Hong Q, Cheng JY, et al. Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer. Onco Targets Ther. 2015;8:549-55doi: 10.2147/OTT.S76879.
Jia, X. Q., Hong, Q., Cheng, J. Y., Li, J. W., Wang, Y. J., Mo, M., Shao, Z. M., Shen, Z. Z., & Liu, G. Y. (2015). Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer. OncoTargets and therapy, 8549-55. https://doi.org/10.2147/OTT.S76879
Jia, Xiao-Qing, et al. "Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer." OncoTargets and therapy vol. 8 (2015): 549-55. doi: https://doi.org/10.2147/OTT.S76879
Jia XQ, Hong Q, Cheng JY, Li JW, Wang YJ, Mo M, Shao ZM, Shen ZZ, Liu GY. Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer. Onco Targets Ther. 2015 Mar 03;8:549-55. doi: 10.2147/OTT.S76879. eCollection 2015. PMID: 25767399; PMCID: PMC4354449.
Copy Download .nbib Format: NLM
Aromatase expression in lung cancer.

The Lancet. Oncology

Paterlini M.
PMID: 28581421
Lancet Oncol. 2007 Dec;8(12):1060. doi: 10.1016/S1470-2045(07)70366-2. Epub 2007 Dec 03.

No abstract available.

Cite
Paterlini M. Aromatase expression in lung cancer. Lancet Oncol. 2007;8(12):1060doi: 10.1016/S1470-2045(07)70366-2.
Paterlini, M. (2007). Aromatase expression in lung cancer. The Lancet. Oncology, 8(12), 1060. https://doi.org/10.1016/S1470-2045(07)70366-2
Paterlini, Marta. "Aromatase expression in lung cancer." The Lancet. Oncology vol. 8,12 (2007): 1060. doi: https://doi.org/10.1016/S1470-2045(07)70366-2
Paterlini M. Aromatase expression in lung cancer. Lancet Oncol. 2007 Dec;8(12):1060. doi: 10.1016/S1470-2045(07)70366-2. Epub 2007 Dec 03. PMID: 28581421.
Copy Download .nbib Format: NLM
Breast Cancer: Abemaciclib effective in combination with aromatase inhibition.

Nature reviews. Clinical oncology

Sidaway P.
PMID: 29039423
Nat Rev Clin Oncol. 2017 Dec;14(12):714. doi: 10.1038/nrclinonc.2017.169. Epub 2017 Oct 17.

No abstract available.

Cite
Sidaway P. Breast Cancer: Abemaciclib effective in combination with aromatase inhibition. Nat Rev Clin Oncol. 2017;14(12):714doi: 10.1038/nrclinonc.2017.169.
Sidaway, P. (2017). Breast Cancer: Abemaciclib effective in combination with aromatase inhibition. Nature reviews. Clinical oncology, 14(12), 714. https://doi.org/10.1038/nrclinonc.2017.169
Sidaway, Peter. "Breast Cancer: Abemaciclib effective in combination with aromatase inhibition." Nature reviews. Clinical oncology vol. 14,12 (2017): 714. doi: https://doi.org/10.1038/nrclinonc.2017.169
Sidaway P. Breast Cancer: Abemaciclib effective in combination with aromatase inhibition. Nat Rev Clin Oncol. 2017 Dec;14(12):714. doi: 10.1038/nrclinonc.2017.169. Epub 2017 Oct 17. PMID: 29039423.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1524 entries